Array Biopharma Inc.

Novartis Ag

Garlock Sealing Technologies, LLC

Intermune, Inc.

Genentech, Inc.

Astrazeneca Ab

Abbott Laboratories Corporation

Abbvie Inc.

Paul Nichols

Weidong Liu

Peter J Stengel

Christoph Max Krell

Werner Heinz Pachinger

Daniel Zimmermann

Marie-Christine Wolf

Daniel Andreas Niederer

Marian Misun

Sherwin Damdar

Steven Wade Andrews

Yutong Jiang

Pierre Martin

Timothy S Kercher

Bin Wang

Scott D Seiwert

Lawrence M Blatt

Steven J Wittenberger

Jien-Heh J Tien

Steven A King

Lawrence Kolaczkowski

Sou-Jen Chang

Michael S Allen

Daniel J Plata

Sagar Raj Shakya

Michael Lyon

April L Kennedy

Stephen L Condon

Eric J Stoner

Ramiya H Premchandran

Andreas Schumacher

C Todd Eary

Subhash R Patel

Robert J Kaus

Tarek Sammakia

Sukumar Manna

Bradley Barnett

Richard Lynn Dibble

John J Demattei

Michelangelo Scalone

Francis Gosselin

Keith Lee Spencer

John A DeMattei

Chong Han

Michael W McManus

James Gair Ford

Bruno P Hache

Matthew Charles Evans

John Leonard

Hemant H Patel

Chad Yoder

James Drago

Wayne Evans

Zackary D Crane

Keena Green

Bradley R Barnett

Michael Mcmanus

A spiral wound gasket includes a resilient sealing element including spirally wound, alternating layers of metal banding and winding fill material that incorporates a significant quantity of talc with quantities of fiber and binder. Either or both of an outer guide ring and inner guide ring may extend from peripheral outer and inner surfaces of the sealing element. Embodiments of the gasket overlay one or both axial faces of the sealing element with a layer facing material that incorporates a significant quantity of talc with quantities of fiber and binder.

Spiral wound gasket

A reinforced gasket material. A non-metallic scrim layer is interposed between layers of gasket material to provide strength to the gasket material. The layers of the gasket material can include binding agent to aid adhering to each other and to the non-metallic scrim layer. The non-metallic scrim layer can also be coated in binding agent. The layers of the gasket material can include high-temperature sealing material, compressed fiber, exfoliated graphite, or polytetrafluoroethylene.

Flexible reinforced gasket

The present invention relates to processes for preparing 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, processes for preparing crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, and intermediates useful therefore. Also provided herein are pharmaceutical compositions comprising this crystallized compound.

Preparation of and formulation comprising a MEK inhibitor

The invention provides processes of preparation thereof useful in the preparation of compounds that can be used as CHK1 inhibitors.

Process for preparing a compound

An extreme temperature gasket material capable of withstanding temperatures in excess of 850&#xb0; F. is provided. The extreme temperature gasket generally includes an inorganic filler, an inorganic fiber, and an organic binder. In some embodiments, the inorganic filler is from 75 to 90 wt % of the gasket material and can include submicron-sized talc particles. The inorganic fiber can be from 5 to 20 wt % of the gasket material and can include silicic acid fiber. The binder can be a latex emulsion and can be present in the gasket material in the range of from 1 to 5 wt % of the gasket material. The gasket material also can include additives, such as flocculant and defoamer. In some embodiments, the amount of organic material present in the gasket material is limited to less than 5 wt % of the gasket material.

Extreme temperature gasket and method of making the same

The present invention relates to processes for preparing 6-(4-bromo-2-fluorophenylamino)-7-fluoro -3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, processes for preparing crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, and intermediates useful therefore. Also provided herein are pharmaceutical compositions comprising this crystallized compound.

The embodiments provide compounds of the general Formulae I through general Formula VIII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Macrocyclic inhibitors of hepatitis C virus replication

Provided are methods for the synthesis of heterocyclic compounds such as benzimidazole carboxylic acid core structures having Formula Ia-2 and their synthetic intermediates: wherein X, X, X, R, Rand Rare as defined herein. Compounds of Formula Ia-2 and their synthetic intermediates can be used to prepare heterocyclic derivatives such as benzimidazole derivatives. 

SNAR process for preparing benzimidazole compounds

Growing community of inventors

Boulder, CO, United States of America

Paul Nichols